What is Lifesci Capital’s Forecast for AVDL Q2 Earnings?

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) – Equities research analysts at Lifesci Capital issued their Q2 2026 earnings estimates for Avadel Pharmaceuticals in a report issued on Wednesday, September 3rd. Lifesci Capital analyst F. Brisebois expects that the company will post earnings per share of $0.19 for the quarter. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. Lifesci Capital also issued estimates for Avadel Pharmaceuticals’ Q3 2026 earnings at $0.23 EPS, Q4 2026 earnings at $0.23 EPS and FY2026 earnings at $0.73 EPS.

A number of other analysts have also weighed in on AVDL. HC Wainwright reissued a “buy” rating and issued a $24.00 price target (up previously from $22.00) on shares of Avadel Pharmaceuticals in a report on Friday, August 8th. Wall Street Zen raised shares of Avadel Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 9th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Avadel Pharmaceuticals in a report on Friday, August 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Avadel Pharmaceuticals in a research note on Thursday, May 8th. Finally, UBS Group raised their price objective on shares of Avadel Pharmaceuticals from $13.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, August 21st. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Avadel Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $19.14.

Avadel Pharmaceuticals Price Performance

Shares of Avadel Pharmaceuticals stock opened at $14.99 on Thursday. The firm has a market cap of $1.46 billion, a P/E ratio of -499.67 and a beta of 1.58. The firm has a 50 day simple moving average of $11.87 and a 200 day simple moving average of $9.69. Avadel Pharmaceuticals has a fifty-two week low of $6.38 and a fifty-two week high of $16.66.

Avadel Pharmaceuticals (NASDAQ:AVDL) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.08. The business had revenue of $68.13 million during the quarter, compared to analyst estimates of $60.28 million. Avadel Pharmaceuticals had a negative net margin of 1.32% and a negative return on equity of 3.73%. Avadel Pharmaceuticals’s revenue for the quarter was up 64.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.14) earnings per share. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Avadel Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in AVDL. Nisa Investment Advisors LLC boosted its position in shares of Avadel Pharmaceuticals by 164.5% during the second quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $29,000 after purchasing an additional 2,055 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Avadel Pharmaceuticals during the second quarter worth $65,000. Tower Research Capital LLC TRC boosted its position in shares of Avadel Pharmaceuticals by 217.5% during the second quarter. Tower Research Capital LLC TRC now owns 8,795 shares of the company’s stock worth $78,000 after purchasing an additional 6,025 shares in the last quarter. Exencial Wealth Advisors LLC bought a new position in shares of Avadel Pharmaceuticals during the first quarter worth $82,000. Finally, Thoroughbred Financial Services LLC bought a new position in shares of Avadel Pharmaceuticals during the first quarter worth $82,000. 69.19% of the stock is owned by institutional investors.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.